Literature DB >> 11146563

What is changing in the natural history of chronic lymphocytic leukemia?

S Molica1, D Levato.   

Abstract

BACKGROUND AND OBJECTIVES: In the last few years there has been a trend towards an improvement in overall survival of patients with chronic lymphocytic leukemia (CLL). Studies based on tumor registries of the general population or including patients referred to hematologic institutions have analyzed reasons for these changes. However, results need to be validated on independent series. DESIGN AND METHODS: We retrospectively evaluated 518 CLL patients diagnosed at our institution between January 1970 and December 1998. In this cohort of patients we looked at characteristics affecting natural history such as age and sex distribution, stage at diagnosis, survival probability and impact of the disease status on the actuarial survival. Trends in these variables were analyzed after splitting the whole series into three groups according to the period in which the diagnosis was made. Group I consisted of 75 patients diagnosed between 1970 and 1979, group II consisted of 149 patients diagnosed in the period 1980--1989, group III was composed of 293 patients diagnosed between 1991 and 1998.
RESULTS: Age and sex distribution did not reflect different periods of diagnosis. The proportion of patients in whom diagnosis was established in low clinical stage (stage A) was higher in the group III (72%) than in groups I or II (26.3% and 50.3%, respectively) (p < 0.0001). Differences in the stage distribution affected life-expectancy which was longer for patients diagnosed in the nineties (median survival, 93 months) than in those diagnosed in the eighties (median survival, 54 months) or in the seventies (median survival, 38 months) (p < 0.0001). Finally, survival analyses by stage showed an improvement of life-expectancy when dealing with patients of high risk category (p =0.005). INTERPRETATION AND
CONCLUSIONS: CLL patients diagnosed in the last decade enjoy the best clinical outcome, mostly as a result of a greater proportion of patients in the low-risk clinical stage and a relatively longer survival of the high risk group. It is not clear whether these changes represent true modifications of the natural history of CLL. At the beginning of the third millennium CLL continues to be a fatal disease with a significant impact on life-expectancy.

Entities:  

Mesh:

Year:  2001        PMID: 11146563

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  13 in total

1.  A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models.

Authors:  R Cailliod; C Quantin; P M Carli; V Jooste; G Le Teuff; C Binquet; M Maynadie
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

2.  Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group.

Authors:  Stefano Molica; Francesca R Mauro; Diana Giannarelli; Francesco Lauria; Agostino Cortelezzi; Maura Brugiatelli; Vincenzo Liso; Antonio Cuneo; Robin Foà
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

3.  The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.

Authors:  Stefano Molica; Francesca R Mauro; Vincenzo Callea; Diana Giannarelli; Francesco Lauria; Bruno Rotoli; Agostino Cortelezzi; Vincenzo Liso; Robin Foà
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

4.  Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia.

Authors:  Juhi Ojha; Jackline Ayres; Charla Secreto; Renee Tschumper; Kari Rabe; Daniel Van Dyke; Susan Slager; Tait Shanafelt; Rafael Fonseca; Neil E Kay; Esteban Braggio
Journal:  Blood       Date:  2014-11-06       Impact factor: 22.113

5.  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

6.  Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Timothy G Call; Clive S Zent; Jose F Leis; Betsy LaPlant; Deborah A Bowen; Michelle Roos; Kristina Laumann; Asish K Ghosh; Connie Lesnick; Mao-Jung Lee; Chung S Yang; Diane F Jelinek; Charles Erlichman; Neil E Kay
Journal:  Cancer       Date:  2012-07-03       Impact factor: 6.860

7.  Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia.

Authors:  Shanique Palmer; Curtis A Hanson; Clive S Zent; Luis F Porrata; Betsy Laplant; Susan M Geyer; Svetomir N Markovic; Timothy G Call; Deborah A Bowen; Diane F Jelinek; Neil E Kay; Tait D Shanafelt
Journal:  Br J Haematol       Date:  2008-04-01       Impact factor: 6.998

8.  Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden.

Authors:  Sigurdur Y Kristinsson; Paul W Dickman; Wyndham H Wilson; Neil Caporaso; Magnus Björkholm; Ola Landgren
Journal:  Haematologica       Date:  2009-09       Impact factor: 9.941

9.  B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome.

Authors:  Tait D Shanafelt; Neil E Kay; Greg Jenkins; Timothy G Call; Clive S Zent; Diane F Jelinek; William G Morice; Justin Boysen; Liam Zakko; Susan Schwager; Susan L Slager; Curtis A Hanson
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

10.  The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Deborah A Bowen; Chaya Venkat; Susan L Slager; Clive S Zent; Neil E Kay; Megan Reinalda; Han Tun; Jeff A Sloan; Timothy G Call
Journal:  Leuk Res       Date:  2008-07-25       Impact factor: 3.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.